公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2004 | Lack of interferon sensitivity-determining region in the genome of hepatitis B virus genotype Ba | CHUN-JEN LIU ; PEI-JER CHEN ; Lai M.-Y.; Chen T.-C.; HURNG-YI WANG ; Huang W.-L.; JIA-HORNG KAO ; DING-SHINN CHEN | Antiviral Therapy | 9 | 8 | |
2001 | Lamivudine treatment for hepatitis B reactivation in HBsAg carriers after organ transplantation: A 4-year experience | CHUN-JEN LIU ; Lai M.-Y.; PO-HUANG LEE ; NAI-KUAN CHOU ; Chu S.-H.; PEI-JER CHEN ; JIA-HORNG KAO ; Jen Y.-M.; DING-SHINN CHEN | Journal of Gastroenterology and Hepatology (Australia) | 36 | 32 | |
2019 | Large and middle hepatitis B surface antigen: The lower the better? | Lin H.-H.; TAI-CHUNG TSENG ; JIA-HORNG KAO | Gut | 1 | 1 | |
2021 | Last Mile to Microelimination of Hepatitis C Virus Infection Among People Living With Human Immunodeficiency Virus | CHEN-HUA LIU ; JIA-HORNG KAO | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 7 | 6 | |
1996 | Least microtransfusion from mother to fetus in elective cesarean delivery | HO-HSIUNG LIN ; JIA-HORNG KAO ; HONG-YUAN HSU ; Mizokami M.; Hirano K.; DING-SHINN CHEN | Obstetrics and Gynecology | 62 | 47 | |
2016 | Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus | Chuang W.-L.; Chien R.-N.; Peng C.-Y.; Chang T.-T.; Lo G.-H.; Sheen I.-S.; Wang H.-Y.; Chen J.-J.; Yang J.C.; Knox S.J.; Gao B.; Garrison K.L.; Mo H.; Pang P.S.; Hsu Y.-C.; Hu T.-H.; Chu C.-J.; JIA-HORNG KAO | Journal of Gastroenterology and Hepatology (Australia) | 24 | 20 | |
2022 | Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4–6 infection: Real-world evidence from a nationwide registry in Taiwan | Lo C.-C.; Huang C.-F.; Cheng P.-N.; Tseng K.-C.; Chen C.-Y.; Kuo H.-T.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; Chen C.-H.; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Chang T.S.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Chen C.-T.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Mo L.-R.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Hsiung C.-K.; Kao C.-N.; Tsai P.-C.; CHEN-HUA LIU ; Lee M.-H.; CHUN-JEN LIU ; Dai C.-Y.; Chuang W.-L.; Lin H.-C.; JIA-HORNG KAO ; Yu M.-L.; TACR investigators | Journal of the Formosan Medical Association | 4 | 0 | |
1995 | Letter | HO-HSIUNG LIN ; JIA-HORNG KAO ; PEI-JER CHEN ; DING-SHINN CHEN | The Journal of Pediatrics | |||
2010 | Letter to the editor | Wang C.-C.; JIA-HORNG KAO | New England Journal of Medicine | 2 | ||
2023 | Letter to the Editor: Hepatic steatosis and glycemic burden in chronic hepatitis B | SHANG-CHIN HUANG ; JIA-HORNG KAO | Hepatology (Baltimore, Md.) | 1 | 1 | |
2023 | Letter to the Editor: Learning more about the safety of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma | CHIA-CHI WANG ; JIA-HORNG KAO | Hepatology | 0 | 0 | |
2022 | Letter to the editor: New kid in the playground: HBcrAg and risk of HCC | Wu J.-W.; TAI-CHUNG TSENG ; JIA-HORNG KAO | Hepatology | 0 | 0 | |
2024 | Letter to the Editor: Statement of steatotic liver disease-A great leap toward the global standardization | Wang, Chia-Chi; Cheng, Yu-Ming; JIA-HORNG KAO | Hepatology (Baltimore, Md.) | 2 | 0 | |
2019 | Letter: contraindicated drug-drug interactions before and after initiation of direct-acting anti-viral agents in chronic hepatitis C patients in Taiwan. Authors’ reply | CHEN-HUA LIU ; JIA-HORNG KAO | Alimentary Pharmacology and Therapeutics | 0 | 0 | |
2020 | Letter: elevated aspartate aminotransferase and aspartate aminotransferase to alanine aminotransferase ratio predicts poor survival in hepatocellular carcinoma after resection—Authors' reply | Wai-Sun Wong V.; JIA-HORNG KAO | Alimentary Pharmacology and Therapeutics | 1 | 1 | |
2021 | Letter: elevated HBV DNA predicts poor survival in hepatocellular carcinoma after hepatic resection—authors' reply | TAI-CHUNG TSENG ; JIA-HORNG KAO | Alimentary Pharmacology and Therapeutics | 1 | 1 | |
2017 | letter: HBsAg kinetics-guided interferon therapy for chronic hepatitis D | Kao C.-N.; TUNG-HUNG SU ; JIA-HORNG KAO | Alimentary Pharmacology and Therapeutics | 1 | 1 | |
2022 | Letter: hepatic steatosis and fibrosis in chronic hepatitis B—the chicken-and-egg conundrum | SHANG-CHIN HUANG ; JIA-HORNG KAO | Alimentary Pharmacology and Therapeutics | 2 | 2 | |
2020 | letter: hepatitis B virus infection and risk of multiple myeloma—a meta-analysis of cohort studies. Authors' reply | TUNG-HUNG SU ; CHI-LING CHEN ; JIA-HORNG KAO | Alimentary Pharmacology and Therapeutics | 0 | 0 | |
2017 | Letter: the influence of direct acting agents for hepatitis C, on hepatitis B reactivation | Wang C.-C.; JIA-HORNG KAO | Alimentary Pharmacology and Therapeutics | 0 | 0 |